Logan Zemp, MD

Cancer Focus:
Bladder Cancer, Kidney (Renal Cell) Cancer, Prostate Cancer, Testicular Cancer

Dr. Zemp received his MD from the University of Alberta in Canada, where he also completed a Urology Residency. Most recently, he completed a Urologic Oncology Fellowship at Moffitt Cancer Center. 

Dr. Zemp’s clinical focus is management of urologic malignancies including kidney, bladder, prostate, and testis cancer. His research interests focus on improving post-operative surgical care and the patient experience with those who have undergone major abdominal/pelvic operations, specifically radical cystectomy, using patient-reported outcomes and biometric data.

Education & Training

Fellowship:

• Moffitt Cancer Center - Genitourinary Oncology

Residency:

• University of Alberta Faculty of Medicine & Dentistry - Urology

Medical School:

• University of Alberta Faculty of Medicine & Dentistry - MD

• Fazili A, Jazayeri SB, Rose KM, Guske C, Wen L, Durant A, Prunty M, Bukavina L, Tyson MD, Grass GD, Xu H, Spiess PE, Gilbert SM, Sexton WJ, Zemp L, Pessoa RR, Poch M, Lerner SP, Li R. Cisplatin-ineligible patients with muscle-invasive bladder cancer demonstrate poor long-term survival following immediate radical cystectomy. BJU Int. 2025 Sep. Pubmedid: 40932312.
• Potez M, Jazayeri SB, Guske C, Miller J, Ali J, Carter M, Khambati F, Dhillon J, Sexton W, Zemp L, Manley B, Souza GR, Spiess PE, Beatty M, Pilon-Thomas S, Chahoud J. Feasibility and Functional Reactivity of Expanded Tumor-infiltrating Lymphocytes from Non-clear-cell Renal Cell Carcinoma. Eur Urol. 2025 Sep. Pubmedid: 40962596.
• Zhao D, Khatri VM, Nakashima JY, Chadha J, Chatwal M, Zhang J, Ionescu F, Linscott JA, Li R, Poch M, Sexton W, Yu A, Spiess PE, Zemp L, Gilbert SM, Manley B, Yin V, Jain R, Torres-Roca J, Johnstone P, Yamoah K, Grass GD. Early Detection of Metastatic Progression by Circulating Tumor DNA in Patients Undergoing Bladder-preserving Trimodality Therapy. J Urol. 2025 Nov.101097JU0000000000004849. Pubmedid: 41231842.
• Miyagi H, Yu X, Peak T, Dhillon J, Le C, Wang X, Yoder S, Marchion D, Lu X, Pettaway C, Moran Segura C, Zhang C, Roman Souza G, Yu A, Zemp L, Spiess P, Chahoud J. Progressive T cell exhaustion and predominance of aging tissue associated macrophages with advancing disease stage in penile squamous cell carcinoma. Sci Rep. 2025 Mar.15(1):7703. Pubmedid: 40044748. Pmcid: PMC11882776.
• Jazayeri SB, Fazili A, Sirard RB, Zemp L, Johnstone PAS, Chahoud J, Spiess PE. Outcomes of PeIN at the surgical margin: insights from an organ-sparing penile cancer database. World J Urol. 2025 Jun.43(1):360. Pubmedid: 40478443.
• Li R, Villa NY, Yu X, Johnson JO, Borjas G, Dhillon J, Moran-Segura CM, Kim Y, Francis N, Dorman D, Powers JJ, Sexton WJ, Spiess PE, Poch MA, Zemp L, Gilbert SM, Zhang J, Pow-Sang JM, Anderson ARA, Li T, Wang X, Grass GD, Burke JM, Dinney CPN, Rodriguez PC, Jain RK, Mulé JJ, Conejo-Garcia JR. Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial. Nat Med. 2025 Jan.31(1):176-188. Pubmedid: 39521884.
• Guske C, Jazayeri SB, Harrs C, Rao N, Davaro F, Xu H, Zemp L, Yu A, Gilbert SM, Poch M, Spiess PE, Sexton W, Linscott J, Li R. Assessing the Impact of Treatment Timing Protocols in Clinical Trials for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2025 Aug.8(4):888-892. Pubmedid: 40670271.
• Peak T, Tian Y, Patel A, Shaw T, Obermayer A, Laborde J, Kim Y, Johnson J, Stewart P, Fang B, Teer JK, Koomen J, Berglund A, Marchion D, Francis N, Echevarria PR, Dhillon J, Clark N, Chang A, Sexton W, Zemp L, Chahoud J, Wang L, Manley B. Pathogenic Roles for RNASET2 in Clear Cell Renal Cell Carcinoma. Lab Invest. 2024 May.104(5):102041. Pubmedid: 38431116.
• Shiver L, Sirard R, Spiess PE, Khan F, Manley BJ, Wang C, Zemp L, Bassil C, Huelster HL. Short- and Long-Term Renal Function After Partial Nephrectomy: Comparison of Solitary and Multifocal Renal Masses. Urol Pract. 2024 Mar.11(2):347-355. Pubmedid: 38154008.
• Liveringhouse C, Sim AJ, Zhang J, Jain RK, Naidu SU, Linkowski L, Zemp LW, Yu A, Sexton WJ, Spiess PE, Gilbert SM, Poch MA, Pow-Sang J, Li R, Manley BJ, Vosoughi A, Dhillon J, Xu H, Torres-Roca JF, Johnstone PAS, Yamoah K, Grass GD. A Single Institution Experience in the Management of Localized Neuroendocrine Carcinoma of the Bladder. Clin Genitourin Cancer. 2024 Dec.22(6):102222. Pubmedid: 39353214.
• Linscott JA, Miyagi H, Murthy PB, Yao S, Grass GD, Vosoughi A, Xu H, Wang X, Yu X, Yu A, Zemp L, Gilbert SM, Poch MA, Sexton WJ, Spiess PE, Li R. From Detection to Cure - Emerging Roles for Urinary Tumor DNA (utDNA) in Bladder Cancer. Curr Oncol Rep. 2024 Aug.26(8):945-958. Pubmedid: 38837106.
• Zemp LW, Rudzinski JK, Pettaway CA, Nicholson S, Spiess PE. Management of Bulky Inguinal and Pelvic Lymph Nodes. Urol Clin North Am. 2024 Aug.51(3):335-345. Pubmedid: 38925736.
• Abel EJ, Master VA, Spiess PE, Raman JD, Shapiro DD, Sexton WJ, Zemp L, Patil D, Lauer K, Allen GO, Matin SF, Karam JA. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features. Eur Urol Oncol. 2024 Apr.7(2):266-274. Pubmedid: 37442673.
• Abel EJ, Master VA, Spiess PE, Raman JD, Shapiro DD, Sexton WJ, Zemp L, Patil D, Lauer K, Allen GO, Matin SF, Karam JA. Reply to Eduard Roussel, Riccardo Bertolo, Chiara Ciccarese, et al's Letter to the Editor re: E. Jason Abel, Viraj A. Master, Philippe E. Spiess, et al. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by. Eur Urol Oncol. 2024 Apr.7(2):302-303. Pubmedid: 38000932.
• Davaro F, Davaro E, Rose K, Murthy P, Naidu S, Camperlengo L, Grass GD, Vosoughi A, Jain RK, Zemp L, Yu A, Poch MA, Spiess PE, Gilbert SM, Sexton WJ, Li R. Impact of surgical margin and extent of lymphadenectomy on oncologic outcomes in plasmacytoid urothelial carcinoma. Urol Oncol. 2023 Sep.41(9):389.e7-389.e13. Pubmedid: 36959058.
• Li R, Naidu S, Fan W, Rose K, Huelster H, Grass GD, Vosoughi A, Dhillon J, Kim Y, Gupta S, Jain RK, Zhang J, Zemp L, Yu A, Poch MA, Spiess PE, Pow-Sang J, Gilbert SM, Sexton WJ. Effectiveness of perioperative chemotherapy and radical cystectomy in treating bladder cancer. Urol Oncol. 2023 Nov.41(11):457.e17-457.e24. Pubmedid: 37880002.
• Murthy PB, Naidu S, Davaro F, Spiess PE, Zemp L, Poch M, Jain R, Vosoughi A, Grass GD, Yu A, Sexton WJ, Gilbert SM, Li R. Survival Benefits of Adjuvant Chemotherapy for Positive Soft Tissue Surgical Margins Following Radical Cystectomy in Bladder Cancer with Extravesical Extension. Curr Oncol. 2023 Mar.30(3):3223-3231. Pubmedid: 36975458. Pmcid: PMC10046994.
• Huelster HL, Zemp L, Turner K, Gonzalez BD, Jim H, Gore LR, Gilbert SM. Mobile Postoperative Symptom Intervention Tool and Biometric Monitoring After Radical Cystectomy: Pilot Study Evaluating Feasibility, Usability, and Potential Utility. J Urol. 2023 Feb.209(2):410-421. Pubmedid: 36350586. Pmcid: PMC10316518.
• Esdaille AR, Karam JA, Master VA, Spiess PE, Raman JD, Sharma P, Shapiro DD, Das A, Sexton WJ, Zemp L, Patil D, Allen GO, Matin SF, Wood CG, Jason Abel E. Contemporary Patients Have Better Perioperative Outcomes Following Cytoreductive Nephrectomy: A Multi-institutional Analysis of 1272 Consecutive Patients. Urology. 2023 Dec.182:168-174. Pubmedid: 37690543.
• Shapiro DD, Karam JA, Master VA, Zemp LW, Sexton WJ, Matin SF, Spiess PE, Jason Abel E. Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Daniel D. Shapiro, Jose A. Karam, Logan Zemp, et al. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Uro. Eur Urol. 2023 Aug.84(2):e55-e56. Pubmedid: 37149462.
• Shapiro DD, Karam JA, Zemp L, Master VA, Sexton WJ, Ghasemzadeh A, Schmeusser BN, Davaro F, Peak T, Patil D, Matin S, Spiess PE, Abel EJ. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Urol Open Sci. 2023 Apr.50:43-46. Pubmedid: 36861106. Pmcid: PMC9969293.
• Aydin AM, Cheriyan SK, Reich R, Hajiran A, Peyton CC, Zemp L, Yu A, Li R, Poch MA, Spiess PE, Jain R, Zhang J, Sexton WJ, Gilbert SM. Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer. Urol Oncol. 2022 Oct.40(10):453.e19-453.e26. Pubmedid: 35811208.
• Chakiryan NH, Hajiran A, Kim Y, Aydin AM, Zemp L, Katende E, Nguyen J, Fan W, Cheng CH, Lopez-Blanco N, Chahoud J, Spiess PE, Fournier M, Dhillon J, Wang L, Moran-Segura C, Mulé J, Du D, Yoder SJ, Berglund A, Teer JK, Manley BJ. Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma. Eur Urol Focus. 2022 May.8(3):784-793. Pubmedid: 33994165.
• Hajiran A, Bracco T, Zemp L, Spiess PE. Leveraging innovative therapies with an evolving understanding of the molecular pathogenesis of penile squamous cell carcinoma. Urol Oncol. 2022 May.40(5):173-178. Pubmedid: 32690436.
• Chakiryan NH, Gore LR, Reich RR, Dunn RL, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain RK, Chahoud J, Spiess PE, Manley BJ, Sexton WJ, Hollenbeck BK, Gilbert SM. Survival Outcomes Associated With Cytoreductive Nephrectomy in Patients With Metastatic Clear Cell Renal Cell Carcinoma. JAMA Netw Open. 2022 May.5(5):e2212347. Pubmedid: 35576003. Pmcid: PMC9112069.
• Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain R, Chahoud J, Li R, Sexton W, Manley BJ, Gilbert SM. Comparative effectiveness analysis of first-line immunotherapy versus chemotherapy in metastatic urothelial carcinoma of the bladder. Urol Oncol. 2022 Mar.40(3):107.e11-107.e17. Pubmedid: 34426068.
• Peak T, Zemp L, Spiess P. Will Dynamic Sentinel Lymph Node Biopsy Surpass Inguinal Lymph Node Dissection in High-risk Node-negative Penile Cancer?. Eur Urol Oncol. 2022 Dec.5(6):712-713. Pubmedid: 36336613.
• Aydin AM, Reich RR, Cao B, Cheriyan SK, Hajiran A, Zemp L, Yu A, Poch MA, Sexton WJ, Li R, Gilbert SM. Clinical indications for necessary and discretionary hospital readmissions after radical cystectomy. Urol Oncol. 2022 Apr.40(4):164.e1-164.e7. Pubmedid: 34629281. Pmcid: PMC8960322.
• Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain R, Chahoud J, Poch M, Manley BJ, Li R, Sexton W, Gilbert SM. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer. J Urol. 2021 Oct.206(4):924-932. Pubmedid: 34032503.
• Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain RK, Chahoud J, Spiess PE, Sexton W, Gilbert SM, Manley BJ. Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma. JAMA Netw Open. 2021 May.4(5):e2111329. Pubmedid: 34032854. Pmcid: PMC8150693.
• Li R, Berglund A, Zemp L, Dhillon J, Putney R, Kim Y, Jain RK, Grass GD, Conejo-Garcia J, Mulé JJ. The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures. Front Immunol. 2021 Jun.12:694079. Pubmedid: 34267760. Pmcid: PMC8276102.
• Chakiryan NH, Kimmel GJ, Kim Y, Johnson JO, Clark N, Hajiran A, Chang A, Aydin AM, Zemp L, Katende E, Chahoud J, Ferrall-Fairbanks MC, Spiess PE, Francis N, Fournier M, Dhillon J, Park JY, Wang L, Mulé JJ, Altrock PM, Manley BJ. Geospatial Cellular Distribution of Cancer-Associated Fibroblasts Significantly Impacts Clinical Outcomes in Metastatic Clear Cell Renal Cell Carcinoma. Cancers (Basel). 2021 Jul.13(15). Pubmedid: 34359645. Pmcid: PMC8345222.
• Hajiran A, Zemp L, Aydin AM, Cheryian SK, Pow-Sang JM, Chahoud J, Spiess PE. Topical chemotherapy for penile carcinoma in situ: Contemporary outcomes and reported toxicity. Urol Oncol. 2021 Jan.39(1):72.e1-72.e5. Pubmedid: 33036902.
• Hajiran A, Azizi M, Aydin AM, Zemp L, Peyton CC, Dhillon J, Nealon S, Reich RR, Cao B, Li R, Manley BJ, Sexton WJ, Gilbert SM. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy. J Urol. 2021 Jan.205(1):100-108. Pubmedid: 32783489. Pmcid: PMC7864376.
• Hajiran A, Azizi M, Aydin AM, Zemp L, Peyton CC, Dhillon J, Nealon S, Reich RR, Cao B, Li R, Manley BJ, Sexton WJ, Gilbert SM. Reply By Authors. J Urol. 2021 Jan.205(1):108. Pubmedid: 33095102.
• Adashek JJ, Zhang Y, Skelton WP, Bilotta A, Chahoud J, Zemp L, Li J, Dhillon J, Manley B, Spiess PE. Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation?. Front Oncol. 2021 Feb.10:627025. Pubmedid: 33643921. Pmcid: PMC7902859.
• Chakiryan NH, Kimmel GJ, Kim Y, Hajiran A, Aydin AM, Zemp L, Katende E, Nguyen J, Lopez-Blanco N, Chahoud J, Spiess PE, Fournier M, Dhillon J, Wang L, Moran-Segura C, El-Kenawi A, Mulé J, Altrock PM, Manley BJ. Spatial clustering of CD68+ tumor associated macrophages with tumor cells is associated with worse overall survival in metastatic clear cell renal cell carcinoma. PLoS One. 2021 Apr.16(4):e0245415. Pubmedid: 33882057. Pmcid: PMC8059840.
• Aydin AM, Zemp L, Cheriyan SK, Sexton WJ, Johnstone PAS. Contemporary management of early stage testicular seminoma. Transl Androl Urol. 2020 Jan.9(Suppl 1):S36-S44. Pubmedid: 32055484. Pmcid: PMC6995845.
• Redmond E, Tong S, Zemp L, Hoy N, Rourke KF. Improved artificial urinary sphincter outcomes using a transcorporal cuff placement in patients with a "fragile urethra". Can Urol Assoc J. 2020 Dec.14(12):E621-E624. Pubmedid: 32569562. Pmcid: PMC7704083.
• Mann U, Zemp L, Rourke KF. Contemporary management of renal trauma in Canada: A 10-year experience at a level 1 trauma centre. Can Urol Assoc J. 2019 Jun.13(6):E177-E182. Pubmedid: 30407154. Pmcid: PMC6570592.
• Zemp L, Tong S, Hoy N, Rourke KF. Preoperative pad usage is independently associated with failure of non-adjustable male trans-obturator slings in otherwise well-selected patients. Can Urol Assoc J. 2019 Apr.13(4):120-124. Pubmedid: 30273118. Pmcid: PMC6456352.
• Zemp L, Mann U, Rourke KF. Perinephric Hematoma Size is Independently Associated with the Need for Urological Intervention in Multisystem Blunt Renal Trauma. J Urol. 2018 May.199(5):1283-1288. Pubmedid: 29360530.
• Turner M, Eidemiller S, Martin B, Narver A, Marshall J, Zemp L, Cornell KA, McIntosh JM, McDougal OM. Structural basis for alpha-conotoxin potency and selectivity. Bioorg Med Chem. 2009 Aug.17(16):5894-5899. Pubmedid: 19628399. Pmcid: PMC2754775.